Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.40 |
| ▸ | RELA | Q04206 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28443611 | 0.80 | MGAM (0.61) | MGAMCNR2HDAC8ALDH1A1MAPT | |
| SCHEMBL28605670 | 0.78 | CNR2 (0.62) | MGAMCNR2HDAC8ALDH1A1MAPT | |
| SCHEMBL261633 | 0.74 | MEN1 (0.31) | MAPTMEN1KMT2A | |
| SCHEMBL22501419 | 0.73 | RAB9A (0.50) | MGAMCNR2HDAC8ALDH1A1MAPT | |
| SCHEMBL2646185 | 0.71 | CES2 (0.42) | HDAC8ALDH1A1MAPTLMNAGAA | |
| SCHEMBL12256867 | 0.71 | MGAM (0.64) | MGAMCNR2HDAC8ALDH1A1MAPT | |
| SCHEMBL1375064 | 0.70 | — | — | |
| SCHEMBL22501398 | 0.70 | KDM4E (0.66) | MGAMCNR2HDAC8ALDH1A1MAPT | |
| SCHEMBL8617775 | 0.70 | MGAM (0.49) | MGAMCNR2HDAC8ALDH1A1MAPT | |
| SCHEMBL611196 | 0.70 | MGAM (0.57) | MGAMCNR2HDAC8ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181986-B1 | Process for the preparation of a precursor of montelukast | SYNTHON BV (NL) | 2011-10-19 | — | — | EP | disclosed |
| EP-2181986-A1 | Process for the preparation of a precursor of montelukast | Synthon B.V. (NL) | 2010-05-05 | — | — | EP | disclosed |
| US-7501517-B2 | Process for making montelukast and intermediates therefor | SYNTHON IP, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1740546-A2 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | Synthon B.V. (NL) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105749-A2 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245569-A1 | Process for making montelukast and intermediates therefor | SYNTHON IP INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245569-A1 | Process for making montelukast and intermediates therefor | LTA4H, CYP4A11, LTC4S | MGAM 2468/4885CNR2 2964/4885HDAC8 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.